Safety and effectiveness of a 2009 H1N1 vaccine in Beijing.

  title={Safety and effectiveness of a 2009 H1N1 vaccine in Beijing.},
  author={Jiang Wu and Fujie Xu and Li Lu and Min Lu and Liang Miao and Ting Gao and Wen-yan Ji and Luo-dan Suo and Dong-lei Liu and Rui Ma and Rui Yu and Jiazi Zhangzhu and Weixiang Liu and Yang Zeng and Xiaomei Li and Xuechun Zhang and Xinghuo Pang and Ying Deng},
  journal={The New England journal of medicine},
  volume={363 25},
BACKGROUND After the first monovalent 2009 pandemic influenza A (H1N1) vaccine became available in September 2009, Chinese officials conducted a mass vaccination program in Beijing. We evaluated the safety and effectiveness of the vaccine. METHODS During a 5-day period in September 2009, a total of 95,244 children and adults received the PANFLU.1 vaccine (Sinovac Biotech), a monovalent split-virion vaccine of 15 μg of hemagglutinin antigen without adjuvant. We assessed adverse events after… 

Figures and Tables from this paper

Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea.
The implementation of this active surveillance study demonstrated the safety of both the adjuvanted and non-adjuvanted H1N1 vaccines.
Comparison of adverse events following immunization with pandemic influenza A (H1N1)pdm09 vaccine with or without adjuvant among health professionals in Rio de Janeiro, Brazil.
It is concluded that the two types of vaccines caused no serious AEFI in the studied population and the adjuvanted vaccine was more reactogenic, particularly in the 24 h following vaccination.
Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in maine.
One dose of monovalent pandemic vaccine provided substantial protection against pH1N1 infection among school-aged children.
Influenza Vaccine Effectiveness in Preventing Influenza Illness Among Children During School-based Outbreaks in the 2014–2015 Season in Beijing, China
Children who did not receive the prior season’s vaccine with a homologous A(H3N2) component may have enjoyed greater protection than repeated vaccinees when the vaccine component appeared to be a poor match with circulating strains during 2014–2015.
Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans.
The rate of GBS immediately following pH1N1 vaccination was 57% higher than in person-time unexposed to vaccine, and the excess risk was much smaller than that observed during the 1976 vaccine campaign and was comparable to some previous seasonal influenza vaccine risk assessments.


[A survey on serological epidemiology of influenza A (H1N1) 2009 in Beijing].
Above 15% of the population in Beijing showed protective antibody against influenza A (H1N1) 2009 virus, indicating the development of immunological barrier to this disease had been formed, to some extent.
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.
Vaccination with recent seasonal nonadjuvanted or adjuvanted influenza vaccines induced little or no cross-reactive antibody response to 2009 H1N1 in any age group.
Preexisting Antibody Response against 2009 Pandemic Influenza H1N1 Viruses in the Taiwanese Population
The study shows the presence of some level of cross-reactive antibody in Taiwanese persons 50 years old or older, and the elderly subjects who may already have been exposed to the 1918 virus had high titers of neutralizing antibody to the 2009 pH1N1 virus.
Epidemiological investigation of an outbreak of pandemic influenza A (H1N1) 2009 in a boarding school: serological analysis of 1570 cases.
  • Tiegang Li, Yang Liu, Bojian Zheng
  • Medicine
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • 2011
Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.
Surveillance of the 2009 H1N1 virus in China shows that the majority of those infected have a mild illness, and the duration of infection may be shortened if oseltamivir is administered.
Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.
Because of an increase in the number of reports of Guillian-Barre syndrome (GBS) following A/New Jersey influenza vaccination, the National Influenza Immunization Program was suspended December 16,
Effectiveness and Cost-Effectiveness of Expanded Antiviral Prophylaxis and Adjuvanted Vaccination Strategies for an Influenza A (H5N1) Pandemic
This decision model for pandemic planning suggests that stockpiling sufficient adjuvanted vaccine for immunizing 40% of the population is more effective and cost-effective than immunizing a smaller proportion of the Population or providing them with antiviral drugs.